One hundred and forty-two consecutive patients with sustained monomorphic ventricular tachycardia (VT) were investigated. Only 26.1% of VTs were associated with ischemic heart disease (IHD). The induction rate of sustained VT upon electrophysiologic study (EPS) was 82.9% in patients with IHD and 65.3% in non-IHD. Of 76 inducible sustained VTs, pharmacologic therapy was finally selected in 35 cases, ablative therapy in 25 and surgical therapy in 12. Long-term prognosis was compared between groups divided according to type of ventricular arrhythmia induced at final EPS after antiarrhythmic therapy as follows: Group A: complete suppression of VT, Group B: clinical or non-clinical nonsustained VT, Group C: clinical sustained VT. The event rate in IHD was 6.3% in Group A, 44.4% in Group B and 100% in Group C. In non-IHD, the event rate was 24.0%, 25.0% and 75.0% (Groups A, B and C, respectively). Complete suppression of VT showed a good prognosis in IHD, however, a slightly higher recurrence rate was observed in non-IHD. In ablative therapy, some recurrences and sudden deaths were observed in spite of complete suppression of both VTs in both the IHD and non-IHD groups. Review of the efficacy of antiarrhythmic procedures is recommended during the follow-up period. (Jpn Heart J 1996; 37: 73-84) 
monomorphic sustained VT seen in our institute, and second, evaluate the longterm prognosis of antiarrhythmic therapy guided by electrophysiologic study (EPS).
SUBJECTS AND METHODS

Study of patients:
Between April 1984 and September 1994, EPS was carried out in 142 consecutive patients referred for evaluation of monomorphic sustained VT. The characteristics of the patients are shown in Table I . Electrophysiologic study: EPS was performed in the nonsedated and postabsorptive state after obtaining written consent from the patient. Our protocol of induction of VT has been previously reported.4-6) Briefly, single and double extrastimuli (triple, if necessary) were given at two basic drives: 600 and 400 msec. Ventricular rapid pacing at a cycle length of 600-286msec was then performed for 5-15sec. This electrical stimulation was delivered at two sites of the right ventricle at the apex and the outflow tract. If VT was not induced, isoproterenol was administered to increase the sinus rate by 20% and the induction protocol was repeated. When VT was not induced in the right ventricle, extrastimuli and rapid pacing were performed in the left ventricle. Stimuli were given at twice the diastolic threshold and 2msec of pulse width using a programmable cardiac stimulator (Fukuda Denshi Co., Cardiac Stimulator BC-02A). Intracardiac local electrograms of the ventricle were filtered at 30 and 500Hz and recorded simultaneously with surface ECG leads I, II, and V1 at a paper speed of 100-200mm/sec (Siemens-Elema, Mingograf 82). In case of a hemodynamically stable VT, overdrive pacing was performed to confirm the criteria of entrainment5-8) as well as to terminate it. Endocardial mapping was performed to determine the site of VT origin.9-11) Antiarrhythmie therapy: Pharmacologic therapy: When VT was induced in the control state, procainamide was first administered intravenously at a dosage of 600mg. When VT was still inducible, procainamide was added at a dose of up to 1000-1500mg (usually less than 1000mg) and the induction protocol was repeated. Administration of other drugs was as follows: procainamide 2.0-3.0g/ day (orally: PO), disopyramide 50-100mg (intravenously: TV) or 300-400mg 1 (100%) in Group C. Using Kaplan-Meier life table analysis in IHD (Figure 1 ), there were no significant differences in recurrence between Groups A and B (p=0.056) because of the small numbers of patients studied within each subgroup. However, Group A of IHD showed better prognoses than Group B. Life table analysis could not be applied to Group C of IHD because it had only one case.
In non-IHD patients, the event rate was 6 of 25 (24.0%) in Group A, 2 of 8 (25.0%) in Group B and 3 of 4 (75.0%) in Group C. Sudden death occured in 1 patient (4.0%) in Group A, 1 (20.0%) in Group B, and 1 (25.0%) in Group C. There were also no significant differences in life table analysis between each group (Figure 2) , however, Groups A and B showed similar prognoses and better No statistical differences in ejection fraction were observed among the groups for IHD and non-IHD. Prognoses of patients whose VTs were completely suppressed (Group A) are shown according to the therapies, antiarrhythmic drugs ( Figure 3 ) and ablative therapies (Figure 4) . The drug therapy of VT of IHD showed excellent prognosis, however, the non-IHD group showed recurrence in 3 patients. After ablative therapy, VT of IHD also had a better prognosis, however, both IHD and non-IHD groups had a case of sudden death one year after treatment with ablative therapies. There were no significant differences because of the small number of patients.
DISCUSSION
Clinical and electrophysiologic characteristics of VT: Ischemic heart disease is the most common cardiac disorder in patients with monomorphic sustained VT in Western countries.24) Re-entry is considered to be the underlying mechanism of most monomorphic sustained VTs, and transient entrainment with rapid pacing highly demonstrates strong evidence of re-entry. Electrophysiologic characteristics of the re-entrant circuit have been investigated, [5] [6] [7] [8] 16, 17, 25) however, the efficacy of antiarrhythmic drug therapy is limited and not predictable. [26] [27] [28] [29] [30] In VT unassociated with non-ischemic heart disease, re-entry is also shown to be the most common underlying mechanism in case of inducible monomorphic sustained VT.6) As reported by Naccarelli et al,31) the induction rate and prognoses might be different between VT with and without IHD.
In the present study, only 26.1% of patients with monomorphic sustained VT had IHD as the underlying heart disease and their cardiac function was slightly better than that of IHD in previous reports.5-8,16,17) Seventy-seven patients (73.9%) had VT unassociated with coronary heart disease or no demonstrable heart disease.
Inducibility of VT in IHD was slightly lower in the present study than that reported earlier,31,12) however, this might be partly due to the fact that some patients had incessant VT. The inducibility of non-IHD was as high as that reported by Naccarelli.31 EPS-guided assessment of the efficacy of antiarrhythmic therapies:
The efficacy of drugs and ablative therapies has been determined by EPS.26-30) An optimal stimulation protocol and the end point in EPS guided judgment is, however, still controversial. More aggressive protocols may result in more non-clinical ventricular arrhythmias.32) In some recent studies, less aggressive protocols Jpn Heart J January 1996 have been used with most patients. 29, 10) The end point of our antiarrhythmic therapy was suppression of monomorphic sustained VT which had been induced in the control state.24) However, ventricular arrhythmias sometimes remain inducible after antiarrhythmic therapies. In this study, we divided the patients according to the result of EPS into three subgroups: Groups A-C and long-term prognoses were analyzed. The change of difficulty in inducing VT was not taken into consideration in this study.26) Long-term follow up: In our study, Group A of IHD showed a 6.3% recurrence rate (Table IV) . In contrast, recurrence and sudden death were observed more frequently in Group B (44.4%). Complete suppression of ventricular arrhythmia during acute drug testing in EPS has been reported to predict longterm prognoses. [26] [27] [28] In VT of IHD, our patients with noninducible ventricular arrhythmias after the anti-arrhythmic procedure also showed good long-term prognosis ( Figure 1 ). In non-IHD patients, Naccarelli et al31) showed that complete suppression is a predictor of a good prognosis in non-IHD patients. In our study, fewer sudden deaths were observed during the follow-up in Group A, however, a similar recurrence rate was observed in the patients whose VTs were completely suppressed (Group A) and in patients whose non-sustained VTs were still inducible (Group B) (Table IV) . Complete suppression of ventricular arrhythmia in EPS may not predict a good prognosis in non-IHD patients (Figure 2 ). Variable underlying diseases are involved in this study and they are different from Naccarelli's. Progressive degeneration of the myocardium may be one of the reasons why effective agents in the acute phase became ineffective.
Some sudden deaths were observed during the follow-up period in patients whose VTs were treated with ablative therapy and which were completely suppressed in acute EPS guided judgments. Chronic fibrosis in the ablated myocardium may be attributed to such recurrences, however, few studies have reported the electrophysiologic characteristics of the re-entrant circuit in the chronic phase after ablated therapy. Further studies are indispensable. Review of the efficacy is recommended at one year after ablated therapy. Limitation of study: Amiodarone and dl-sotalol were not commonly used until recently, and a higher efficacy might be expected. However, the overall data would be unchanged even if patients treated with class III drugs had been excluded.
Each group consisted of only a small number of patients so more data is needed.
Conclusion:
Complete suppression of VT was associated with a good prognosis, with the best being in IHD patients. In non-IHD, slightly higher rates of recurrence or sudden death were observed. Some patients with VTs of both IHD and non-IHD died suddenly one year after being treated with ablative therapy, even if VTs had been completely suppressed in acute EPS guided assessment. It should be mandatory to reassess the efficacy of either intervention during the follow-up period.
